Compare · BSX vs IRMD
BSX vs IRMD
Side-by-side comparison of Boston Scientific Corporation (BSX) and iRadimed Corporation (IRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and IRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 60.7x IRMD ($1.19B).
- Over the past year, BSX is down 51.1% and IRMD is up 55.6% - IRMD leads by 106.7 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 5 for IRMD).
- BSX has more recent analyst coverage (25 ratings vs 1 for IRMD).
- Company
- Boston Scientific Corporation
- iRadimed Corporation
- Price
- $48.97+0.84%
- $94.38+0.33%
- Market cap
- $72.16B
- $1.19B
- 1M return
- -13.46%
- +8.63%
- 1Y return
- -51.05%
- +55.62%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
iRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest IRMD
- Director Scharen-Guivel Hilda Frederique sold $285,000 worth of shares (3,000 units at $95.00), decreasing direct ownership by 35% to 5,598 units (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $226,507 worth of shares (2,500 units at $90.60) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $691,044 worth of shares (7,500 units at $92.14) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $657,265 worth of shares (7,500 units at $87.64) as part of a pre-agreed trading plan (SEC Form 4)
- IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by iRadimed Corporation
- CEO, President, Chairman Susi Roger E. sold $631,341 worth of shares (7,500 units at $84.18) as part of a pre-agreed trading plan (SEC Form 4)
- CEO, President, Chairman Susi Roger E. sold $642,862 worth of shares (7,500 units at $85.71) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by iRadimed Corporation
- iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits